

Synthesis of Enantiopure ($\alpha S,\beta S$)- or ($\alpha R,\beta S$)- β -Amino Alcohols by Complete Regioselective Opening of Aminoepoxides by Organolithium Reagents LiAlH_4 or LiAlD_4

José M. Concellón,* Pablo L. Bernad, Virginia del Solar, and José Ramón Suárez


Departamento de Química Orgánica e Inorgánica, Facultad de Química, Universidad de Oviedo, Julián Clavería, 8, 33071 Oviedo, Spain

Santiago García-Granda and M. Rosario Díaz

Departamento de Química Física y Analítica, Facultad de Química, Universidad de Oviedo, Julián Clavería, 8, 33071 Oviedo, Spain

jmcg@fq.uniovi.es

Received March 29, 2006



The reaction of chiral ($2R,1'S$)- or ($2S,1'S$)-2-(1-aminoalkyl)epoxides, **1** or **2** with a variety of organolithium compounds to obtain the corresponding ($\alpha S,\beta S$)- or ($\alpha R,\beta S$)- β -amino alcohols in enantiopure form is reported. In both cases, the opening of the oxirane ring at C-3 proceeded with total regioselectivity. Moreover, the ring opening of aminoepoxides **1** or **2** by hydride (utilizing LiAlH_4) to obtain the corresponding ($2S,3S$)- or ($2R,3S$)-3-aminoalkan-2-ols is also described. The reaction of **1** or **2** with LiAlD_4 in place of LiAlH_4 gave the corresponding ($2S,3S$)- or ($2R,3S$)-3-amino-1-deuteroalkan-2-ols.

Introduction

Enantiopure β -aminoalkanols are important building blocks and have been used to prepare a large number of biologically active natural and synthetic compounds,¹ including unnatural amino acids.² The former compounds have also been used as chiral auxiliaries for asymmetric synthesis.³ Consequently, a large number of syntheses of enantiopure β -amino alcohols have been published. The most common and practical method for

the synthesis of these compounds was the direct aminolysis of epoxides.⁴ The opening of oxiranes by amines was limited by the high temperature, long reaction time, and excess of amine required. In addition, often the method failed when poorly nucleophilic amines or sterically crowded amines or epoxides were used. Finally, the total control of regioselectivity of the ring opening was, generally, unresolved. For this reason, a general synthesis of enantiopure β -amino alcohols with complete selectivity, in which several enantiopure diastereoisomers could be available, would be still desirable.

Previously, we reported the efficient synthesis of both enantiopure ($2R,1'S$)- or ($2S,1'S$)-2-(1-aminoalkyl)epoxides **1** or **2** by total stereoselective reduction of enantiopure α -amino- α' -chloroketones with LiAlH_4 or by highly stereoselective addition reaction of iodomethyl lithium to α -aminoaldehydes, respectively.⁵ Building on these results, we described, more recently,

(1) (a) Corey, E. J.; Zhang, F. *Angew. Chem., Int. Ed. Engl.* **1999**, *38*, 1931–1934. (b) Johannes, C. W.; Visser, M. S.; Weatherhead, G. S.; Hoveyda, A. H. *J. Am. Chem. Soc.* **1998**, *120*, 8340–8347. (c) Chang, B. L.; Ganeshan, A. *Bioorg. Med. Chem. Lett.* **1997**, *7*, 1511–1514. (d) Rogers, G. A.; Parsons, S. M.; Anderson, D. S.; Nilson, L. M.; Bahr, B. A.; Kornreich, W. D.; Kaufman, R.; Jacobs, R. S.; Kirtman, B. *J. Med. Chem.* **1989**, *32*, 1217–1230.

(2) (a) O'Brien, P. *Angew. Chem., Int. Ed.* **1999**, *38*, 326–329. (b) Li, G.; Chang, H. T.; Sharpless, K. B. *Angew. Chem., Int. Ed. Engl.* **1996**, *35*, 451–454.

(3) Ager, D. J.; Prakash, I.; Schaad, D. R. *Chem. Rev.* **1996**, *96*, 835–875.

(4) (a) Hodgson, D. M.; Gibbs, A. R.; Lee, G. P. *Tetrahedron* **1996**, *52*, 14361–14384. (b) Bergmeier, S. C. *Tetrahedron* **2000**, *56*, 2561–2576. (d) Hanson, R. M. *Chem. Rev.* **1991**, *91*, 437–476.




FIGURE 1.

the highly regioselective ring opening of these aminoepoxides with ketones,⁶ nitriles,⁷ and carboxylic acids.⁸

Very recently, we reported the transformation of aminoepoxides **1** and **2** into enantiopure allylamines **3** by reaction with various organolithium compounds.⁹ To investigate the scope of the synthetic applications of the reaction between the same enantiopure aminoepoxides **1** and **2** and organolithium compounds, we report herein the nucleophilic opening of the oxirane ring of **1** or **2** with a variety of organolithium compounds, under different reaction conditions to those previously reported in the synthesis of allylamines.⁹ So, we describe the reaction conditions to obtain enantiopure ($\alpha S,\beta S$)- or ($\alpha R,\beta S$)- β -amino alcohols **4** or **5** (instead of the allylamines previously reported) by reaction of various organolithium compounds with compounds **1** or **2**. The ring opening at C-3 proceeded with total regioselectivity, and β -amino alcohols **4** or **5** were readily available, in enantiopure form. To the best of our knowledge, only one example of the ring opening of aminoepoxides **1** or **2** with organolithium compounds was previously described.¹⁰ Moreover, the ring opening of aminoepoxides **1** or **2** by LiAlH₄ to obtain the corresponding (2S,3S)- or (2R,3S)-3-aminoalkan-2-ols **6** or **7** is also reported. When LiAlD₄ was used instead of LiAlH₄, the corresponding deuterated amino alcohols **8** and **9** were obtained.

Results and Discussion

Synthesis of ($\alpha S,\beta S$)- or ($\alpha R,\beta S$)- β -Amino Alcohols **4 or **5** Using Organolithium Compounds.** In our recent paper,⁹ in which we described the synthesis of allylamines **3** by reaction of aminoepoxides **1** with organolithium compounds, the transformation was promoted by the abstraction of a proton of the oxirane ring by the organolithium compound because of its strong basic character. These previous results prompted us to find other different reaction conditions in order to use the organolithium compounds such as nucleophiles instead of bases, so that we could perform the selective ring opening of compounds **1** to obtain the corresponding amino alcohols **4** instead of the allylamines **3** (Figure 1).

Previously, in some of the synthesis of allylamines we detected the formation of β -amino alcohols **4**, as a minor reaction product, when less reactive organolithium compounds were used, such as phenyllithium or methylolithium. This inconvenience was then overcome, and the allylamines were

(5) (a) Barluenga, J.; Baragaña, B.; Alonso, A.; Concellón, J. M. *J. Chem. Soc., Chem. Commun.* **1994**, 969–970. (b) Barluenga, J.; Baragaña, B.; Concellón, J. M. *J. Org. Chem.* **1995**, 60, 6696–6699.

(6) Concellón, J. M.; Suárez, J. R.; García-Granda, S.; Díaz, M. R. *Org. Lett.* **2005**, 7, 247–250.


(7) Concellón, J. M.; Suárez, J. R.; del Solar, V. *J. Org. Chem.* **2005**, 70, 7447–7450.

(8) Concellón, J. M.; Suárez, J. R.; del Solar, V.; Llavona, R. *J. Org. Chem.* **2005**, 70, 10348–10353.

(9) Concellón, J. M.; Suárez, J. R.; del Solar, V. *Org. Lett.* **2006**, 8, 349–351.

(10) For the only example of the reaction of an organolithium compound with aminoepoxide, see the following: Mena, M.; Bonjoch, J. *Tetrahedron* **2005**, 61, 8264–8270.

SCHEME 1. Synthesis of ($\alpha S,\beta S$)- β -Amino Alcohol **4**

TABLE 1. Synthesis of ($\alpha S,\beta S$)- β -Amino Alcohol **4**

entry	4	R ¹	R ²	yield (%) ^a
1	4a	Me	Me	78
2	4b	Me	Allyl	80
3	4c	Me	Ph	72
4	4d	i-Bu	Me	71
5	4e	i-Bu	Allyl	84
6	4f	i-Bu	Ph	76
7	4g	Bn	Me	70
8	4h	Bn	Allyl	89
9	4i	Bn	Ph	78

^a Isolated yields after column chromatography based on the starting aminoepoxide **1**.

isolated as the only product by performing the transformation with longer reaction times. On the basis of these results, and to find the reaction conditions to obtain β -amino alcohols **4** as only product, our initial attempts were carried out utilizing syn-aminoepoxides **1** and methylolithium and with short reaction times. Thus, treatment of a solution of aminoepoxides **1a–c** derived from alanine, leucine, and phenylalanine (R¹ = Me, i-Bu, and Bn) in THF with methylolithium (3 equiv) at 0 °C with short reaction time (30 min) provided a 3:1 mixture of the corresponding allylamine **3** and the β -amino alcohol **4**. No β -amino alcohols were obtained, as only product, by using shorter reaction times.

Taking into account the influence of the solvent in the nucleophilicity and basicity of the organolithium compounds,¹¹ we decided to perform the reaction using diethyl ether instead of THF. Thus, treatment of a solution of aminoepoxides **1** in diethyl ether with methyl, allyl, or phenyllithium at 0 °C afforded, after hydrolysis, the corresponding ($\alpha S,\beta S$)- β -amino alcohol **4** in high yield (Scheme 1 and Table 1).


The reaction with allyllithium could also be performed in THF instead of Et₂O obtaining the corresponding amino alcohol **4**, as the sole product, in similar yields. This result could be obtained as consequence of the higher nucleophilicity of this organolithium compound.

When aminoepoxides **1** were treated with other organolithium reagents, such as *i*-propyl, *n*-butyl, *sec*-butyl, or *tert*-butyl in diethyl ether, no β -amino alcohols were obtained, and the corresponding allylamines were the only isolated product.

The reaction of aminoepoxides **1** derived from alanine, leucine, and phenylalanine with these organolithium reagents was totally regioselective. So, no regioisomers were observed by ¹H and ¹³C NMR analysis (300 MHz) of crude reaction products **4**, within the limits of NMR assay. In addition, ¹H and ¹³C NMR spectra of compounds **4** showed the opening of the oxirane at the C-3 position. The preservation of the absolute configuration of the oxirane in the course of the ring opening and, consequently, the structure of compounds **4** has been proposed on the basis of previous reactions of aminoepoxides **1** with ketones,⁶ nitriles,⁷ and carboxylic acids⁸ and on the single-crystal X-ray analysis of **5i** (see below).

To extend the scope of this reaction, we performed the reaction of *anti*-aminoepoxides **2** with the same organolithium

(11) Najera, C.; Yus, M. *Curr. Org. Chem.* **2003**, 7, 867–926.

SCHEME 2. Synthesis of ($\alpha R, \beta S$)- β -Amino Alcohol 5**TABLE 2. Synthesis of ($\alpha R, \beta S$)- β -Amino Alcohol 5**

entry	5	R¹	R²	de (%) ^a	yield (%) ^b
1	5a	Me	Me	>98 (>98)	80
2	5b	Me	allyl	>98 (>98)	79
3	5c	Me	Ph	>98 (>98)	72
4	5d	i-Bu	Me	89 (91)	68
5	5e	i-Bu	allyl	90 (91)	75
6	5f	i-Bu	Ph	91 (91)	70
7	5g	Bn	Me	91 (92)	69
8	5h	Bn	allyl	92 (92)	80
9	5i	Bn	Ph	91 (92)	77

^a Diastereoisomeric excess determined by ¹H NMR analysis of the crude products 5; de of the starting aminoepoxides 2 is given in parentheses.^b Isolated yields after column chromatography based on the starting aminoepoxide 2.


compounds and under the same reaction conditions (Scheme 2, Table 2). In all cases, the corresponding ($\alpha R, \beta S$)- β -amino alcohols 5 were obtained in good yields, with high selectivity, and no important differences in the yields were observed from aminoepoxide 1 or 2.

The selectivity of the reaction was also determined by ¹H NMR spectroscopy (300 MHz) of the crude mixture of products, showing a mixture of diastereoisomers 5 in the same relationship as the starting aminoepoxides 2. The synthesis of β -amino alcohols 5 with the same diastereoisomeric excess (de) as the starting aminoepoxides 2⁵ was an indirect support of the total selectivity of the ring opening reaction. After purification of compounds 5 by column chromatography, the major diastereoisomer was isolated as a single stereoisomer. The structure of compounds 5 and, consequently, the absolute configuration was established by single-crystal X-ray analysis of 5i.¹² The structure of the other β -amino alcohols 5 as depicted in Scheme 4 was assigned by analogy. The X-ray analysis of 5i, confirmed that the ring opening of the oxirane took place at C-3, the absolute configuration of the oxirane being preserved. In turn, the single-crystal X-ray analysis of 5i confirmed the structure of amino alcohols 4, as depicted in Scheme 1. Therefore, the epoxides 1 or 2 can be opened with total regioselectivity by the organolithium reagents investigated to give the (*S,S*)- or (*R,S*)- β -amino alcohols 4 or 5, exclusively.

Preparation of (2S,3S)- or (2R,3S)-3-Aminoalkan-2-ols 6 or 7 by Using LiAlH₄. The reaction of a solution of aminoepoxides 1 or 2 in THF with LiAlH₄ (1.5 equiv.) afforded, after hydrolysis, the corresponding (2S,3S)- or (2R,3S)-3-aminoalkan-2-ols 6 or 7 in high yield (>80%) (Schemes 3 and 4 and Tables 3 and 4). Similarly to the synthesis of 4 or 5, the reaction of 1 or 2 with LiAlH₄ was not sensitive to the different stereochemistry and structure of the starting epoxides, and similar yields of 6 or 7 were obtained in all cases.

The reaction of aminoepoxides 1 and 2 with LiAlH₄ was also totally regioselective, and no regioisomers or byproducts were observed by ¹H and ¹³C NMR analysis (300 MHz) of crude

(12) CCDC-602397 (5i) contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or the Cambridge Data Centre, 12, Union Road, Cambridge CB21EZ, U.K. Fax: (+44)1223-336.033; or deposit@ccdc.cam.ac.uk).

SCHEME 3. Synthesis of (*S,S*)- β -Amino Alcohols 6 or 8**SCHEME 4. Synthesis of (*R,S*)- β -Amino Alcohols 7 or 9****TABLE 3. Synthesis of (*S,S*)- β -Amino Alcohols 6 or 8**

entry	compound	R¹	yield (%) ^a
1	6a	Me	80
2	6b	i-Bu	81
3	6c	Bn	90
4	8a	Me	82
5	8c	Bn	84

^a Isolated yields after column chromatography based on the starting amino epoxide 1.**TABLE 4. Synthesis of (*R,S*)- β -Amino Alcohols 7 or 9**

entry	compound	R¹	de (%) ^a	yield (%) ^b
6	7a	Me	>98 (>98)	82
7	7b	i-Bu	90 (91)	85
8	7c	Bn	91 (92)	91
9	9a	Me	>98 (>98)	81
10	9c	Bn	90 (92)	83

^a Diastereoisomeric excess determined by ¹H NMR analysis of the crude products 7 or 9; de of the starting aminoepoxides 2 is given in parentheses.^b Isolated yields after column chromatography based on the starting aminoepoxide 2.

reaction products after column chromatography. Synthesis of compounds 6 or 7 previously reported, afforded a mixture of diastereoisomers 6/7¹³ or took place in lower yields.¹⁴ The structure of β -amino alcohols 6 or 7 (opening of the oxirane at C-3) was established on the basis of their ¹H and ¹³C NMR data and by comparison with the ¹H or ¹³C NMR spectroscopic data of the compounds 6a–c and 7b,c, previously prepared by other methods.¹⁴ The regiochemistry of the reaction was in accordance with the observed results in the ring opening of compounds 1 or 2 when different nucleophiles were used.^{6–8}

In view of the utility of isotopically labeled compounds in establishing the mechanisms of organic reactions and of the biosynthesis of many natural compounds,¹⁵ we applied this method to obtain deuterated β -amino alcohols 8 or 9 by using LiAlD₄ instead of LiAlH₄.


No differences were observed during the course of the reaction or on the outcome of the reaction, when aminoepoxides 1 or 2 were treated with LiAlD₄ instead of LiAlH₄ under the same reaction conditions. In this case, the corresponding (2S,3S)- or (2R,3S)-3-amino-1-deuteroalkan-2-ols 8 or 9, respectively,

(13) Reetz, M. T.; Drewes, M. W.; Schmitz, A. *Angew. Chem., Int. Ed. Engl.* **1987**, 26, 1141–1143.

(14) Schwerdtfeger, J.; Kolczewski, S.; Weber, B.; Fröhlich, R.; Hoppe, D. *Synthesis* **1999**, 9, 1573–1592.

(15) Mann, J. *Secondary Metabolism*; Oxford University Press: Oxford, U.K., 1986; p 23.

SCHEME 5. Mechanism Proposed



were obtained in high yield as the only product. Therefore, isotopically labeled with deuterium β -amino alcohols 8 or 9 were readily available from aminoepoxides 1 or 2.

Scheme 5 shows both mechanisms proposed to explain the transformation of aminoepoxides 1 into amino alcohols 4 or into allylamines 3. Thus, the synthesis of allylamines 3 took place by reaction of compounds 1 with 2 equiv of organolithium compound in THF. The first equivalent of the organolithium compound abstracted a proton at the less hindered side of the oxirane ring. Then, the generated oxiranyl anion intermediate 10 suffered an α -elimination affording an α -alkoxy carbeneoid intermediate 11, which reacted with the second equivalent of the organolithium compounds to give a dianion 12. Elimination of lithium oxide from the dianion afforded allylamines 3. An indirect support for this mechanism was provided by the isolation of a 1:1 mixture of the starting aminoepoxide and the corresponding allylamine when the reaction was carried out by using only 1 equiv of organolithium compound.

Alternatively, when the reaction of 1 was carried out with organolithium compounds in Et_2O , a ring opening at the less hindered side C-3 by nucleophilic attack of the organolithium compound would occur affording the intermediate 13, which could be hydrolyzed to give the corresponding ($\alpha S,\beta S$)- β -amino alcohols 3. The total regioselectivity can be explained on the basis of steric grounds. The nucleophilic attack took place at the less hindered side of the oxirane and, moreover, a bulky substituent (dibenzylamino group) is attached at the α -carbon of the substituent alkyl group of the oxirane ring. This observed regiochemistry was in accordance to that observed in other ring opening processes of compounds 1 by different nucleophiles, such as ketones,⁶ nitriles,⁷ and carboxylic acids.^{8,16}

The different reactivity of aminoepoxides 1 with organolithium reagents depending on which solvent was used (Et_2O or THF) could be explained taking into account that in THF, which is a more strongly coordinating solvent than Et_2O , an enhancement of the basicity of the organolithium reagent is produced. So, the organolithium reagent in THF produced the lithiation of the oxirane ring⁹ instead the ring opening which took place in Et_2O .

Similarly, when the reaction of 1 was carried out with $LiAlH_4$ or $LiAlD_4$ the nucleophilic attack of the hydride or deuteride at C-3 of the oxirane afforded the corresponding alcoholate (Scheme 5, $R^2 = H$ or D), which (after treatment with an aqueous saturated solution of NH_4Cl) afforded enantiopure 3-aminoalkan-2-ols 6 or 3-amino-1-deuteroalkan-2-ols 8.

(16) These previous ring openings of the aminoepoxides 1 or 2 with other nucleophiles (ketones, nitriles, and carboxylic acids) were carried out in the presence of $BF_3 \cdot Et_2O$.

A similar mechanism could explain the reaction of aminoepoxides 2 with the organolithium compounds, hydride or deuteride to afford, after hydrolysis, amino alcohols 5, 7, or 9.

Conclusions

We have reported the reaction conditions to transform the chiral ($2R,1'S$)- or ($2S,1'S$)-2-(1-aminoalkyl)epoxides 1 or 2 into enantiopure ($\alpha S,\beta S$)- or ($\alpha R,\beta S$)- β -amino alcohols 4 or 5 by a reaction with a variety of organolithium compounds in diethyl ether. The opening of the oxirane ring at C-3 proceeded with total regioselectivity. Moreover, the ring opening by hydride (using $LiAlH_4$) of aminoepoxides 1 or 2 to obtain the corresponding ($2S,3S$)- or ($2R,3S$)-3-aminoalkan-2-ols 6 and 7 is also reported. The reaction of 1 or 2 with $LiAlD_4$ instead of $LiAlH_4$ afforded the corresponding deuterated β -amino alcohols 8 or 9.

Experimental Section

General Procedure of Synthesis of 4 and 5. To a stirred solution of the corresponding aminoepoxide 1 or 2 (0.2 mmol) in Et_2O (1 mL), the corresponding organolithium (3 equiv) was added at 0 °C. After the mixture was stirred at this temperature for 6 h, an aqueous saturated solution of NH_4Cl (5 mL) was added, and the mixture was stirred at room temperature for 5 min. Then, the aqueous phase was extracted with diethyl ether (3 × 5 mL), and the combined organic layers were dried over anhydrous Na_2SO_4 , filtered, and concentrated in vacuo. Flash column chromatography on silica gel (hexane/EtOAc 20:1) provided pure compounds 4 or 5.

(2S,3S)-2-(Dibenzylamino)pentan-3-ol (4a): colorless oil. $[\alpha]^{25}_D = +42.5$ (c 1.77, $CHCl_3$). 1H NMR (300 MHz, $CDCl_3$): δ 7.38–7.25 (m, 10 H), 4.47 (br s, 1 H), 3.88 (d, $J = 13.3$ Hz, 2 H), 3.46 (ddd, $J = 9.4, 8.3, 2.7$ Hz, 1 H), 3.35 (d, $J = 13.3$ Hz, 2 H), 2.61 (dq, $J = 9.4, 6.8$ Hz, 1 H), 1.59 (ddq, $J = 14.0, 7.2, 2.7$ Hz, 1 H), 1.24–1.10 (m, 1 H), 1.05 (d, $J = 6.8$ Hz, 3 H), 0.98 (t, $J = 7.2$ Hz, 3 H). ^{13}C NMR (50 MHz, $CDCl_3$): δ 138.8 (2 × C), 128.9 (4 × CH), 128.4 (4 × CH), 127.1 (2 × CH), 71.8 (CH), 57.9 (CH), 53.1 (2 × CH_2), 26.3 (CH_2), 9.9 (CH_3), 7.9 (CH_3). MS (70 eV, EI) m/z (%): 265 ($M^+ - H_2O$, <1), 224 (70), 91 (100). HRMS (70 eV): calcd for $C_{19}H_{23}N$ ($M^+ - H_2O$), 265.1830; found, 265.1836. IR (neat): 3422, 2925, 2351, 1604, 1496, 1455, 1377 cm⁻¹. $R_f = 0.37$ (hexane/EtOAc 10:1). Anal. Calcd for $C_{19}H_{25}NO$: C, 80.52; H, 8.89; N, 4.94; O, 5.65. Found: C, 80.65; H, 8.97; N, 4.98; O, 5.60.

(2S,3S)-2-(Dibenzylamino)hept-6-en-3-ol (4b): colorless oil. $[\alpha]^{25}_D = +50.4$ (c 1.44, $CHCl_3$). 1H NMR (300 MHz, $CDCl_3$): δ 7.37–7.27 (m, 10 H), 5.85 (ddt, $J = 17.0, 10.2, 6.6$ Hz, 1 H), 5.07–5.00 (m, 1 H), 4.98–4.94 (m, 1 H), 4.51 (br s, 1 H), 3.86 (d, $J = 13.3$ Hz, 2 H), 3.52 (dt, $J = 9.4, 2.5$ Hz, 1 H), 3.34 (d, $J = 13.3$ Hz, 2 H), 2.60 (dq, $J = 9.4, 6.7$ Hz, 1 H), 2.36–2.24 (m, 1 H), 2.21–2.07 (m, 1 H), 1.64–1.53 (m, 1 H), 1.33–1.22 (m, 1 H), 1.05 (d, $J = 6.7$ Hz, 3 H). ^{13}C NMR (75 MHz, $CDCl_3$): δ 138.8 (2 × C), 138.7 (CH), 128.9 (4 × CH), 128.4 (4 × CH), 127.1 (2 × CH), 114.3 (CH_2), 70.0 (CH), 58.2 (CH), 53.1 (2 × CH_2), 33.0 (CH_2), 29.9 (CH_2), 7.9 (CH_3). MS (70 eV, EI) m/z (%): 309 ($M^+, <1$), 225 (100), 91 (13). HRMS (70 eV): calcd for $C_{21}H_{27}NO$ (M^+), 309.2093; found, 309.2080. IR (neat): 3418, 2935, 2398, 1640, 1603, 1495, 1453, 1414, 1380 cm⁻¹. $R_f = 0.39$ (hexane/EtOAc 10:1). Anal. Calcd for $C_{21}H_{27}NO$: C, 81.51; H, 8.79; N, 4.53; O, 5.17. Found: C, 81.37; H, 8.88; N, 4.58; O, 5.11.

(2S,3S)-3-(Dibenzylamino)-1-phenylbutan-2-ol (4c): colorless oil. $[\alpha]^{25}_D = +1.7$ (c 1.64, $CHCl_3$). 1H NMR (200 MHz, $CDCl_3$): δ 7.34–7.25 (m, 15 H), 4.62 (br s, 1 H), 3.88 (d, $J = 13.3$ Hz, 2 H), 3.78 (ddd, $J = 9.0, 8.6, 2.7$ Hz, 1 H), 3.36 (d, $J = 13.3$ Hz, 2 H), 2.89 (dd, d, $J = 13.7, 2.7$ Hz, 1 H), 2.68 (dq, $J = 9.0, 6.6$ Hz, 1 H), 2.48 (dd, J = 13.7, 9.0 Hz, 1 H), 1.14 (d, $J = 6.6$ Hz, 3 H).

¹³C NMR (50 MHz, CDCl₃): δ 138.6 (3 \times C), 129.2 (2 \times CH), 128.9 (4 \times CH), 128.4 (4 \times CH), 128.1 (2 \times CH), 127.1 (2 \times CH), 125.9 (CH), 71.8 (CH), 57.9 (CH), 53.1 (2 \times CH₂), 40.0 (CH₂), 8.2 (CH₃). MS (70 eV, EI) *m/z* (%): 345 (M⁺, <1), 224 (100), 181 (14), 91 (42), 69 (16). HRMS (70 eV): calcd for C₂₄H₂₇-NO (M⁺), 345.2093; found, 345.2100. IR (neat): 3397, 3028, 2363, 1603, 1495, 1454, 1378 cm⁻¹. *R_f* = 0.34 (hexane/EtOAc 10:1). Anal. Calcd for C₂₄H₂₇-NO: C, 83.44; H, 7.88; N, 4.05; O, 4.63. Found: C, 83.55; H, 7.79; N, 4.00; O, 4.69.

(3S,4S)-4-(Dibenzylamino)-6-methylheptan-3-ol (4d): colorless oil. [α]²⁵_D = +26.7 (*c* 1.35, CHCl₃). ¹H NMR (200 MHz, CDCl₃): δ 7.31–7.22 (m, 10 H), 3.89 (d, *J* = 13.3 Hz, 2 H), 3.45 (d, *J* = 13.3 Hz, 2 H), 3.44–3.39 (m, 1 H), 2.53 (ddd, *J* = 9.1, 6.4, 4.4 Hz, 1 H), 1.81–1.52 (m, 3 H), 1.30–1.14 (m, 2 H), 0.98 (d, *J* = 6.3 Hz, 6 H), 0.96 (t, *J* = 7.3 Hz, 3 H). ¹³C NMR (50 MHz, CDCl₃): δ 139.1 (2 \times C), 130.0 (4 \times CH), 128.4 (4 \times CH), 127.1 (2 \times CH), 72.3 (CH), 60.4 (CH), 53.7 (2 \times CH₂), 35.6 (CH₂), 26.6 (CH₂ and CH), 23.3 (CH₃), 22.9 (CH₃), 10.2 (CH₃). MS (70 eV, EI) *m/z* (%): 307 (M⁺ – H₂O, 2), 251 (71), 69 (100), 57 (74). HRMS (70 eV) calcd for C₂₂H₂₉N (M⁺ – H₂O), 307.2300; found, 307.2327. IR (neat): 3422, 2957, 2350, 1603, 1495, 1454, 1368 cm⁻¹. *R_f* = 0.32 (hexane/EtOAc 10:1). Anal. Calcd for C₂₂H₃₁-NO: C, 81.18; H, 9.60; N, 4.30; O, 4.92. Found: C, 81.03; H, 9.71; N, 4.34; O, 4.86.

(5S,6S)-6-(Dibenzylamino)-8-methylnon-1-en-5-ol (4e): colorless oil. [α]²⁵_D = +10.2 (*c* 2.14, CHCl₃). ¹H NMR (300 MHz, CDCl₃): δ 7.36–7.24 (m, 10 H), 5.86 (ddt, *J* = 17.1, 10.2, 6.7 Hz, 1 H), 5.04 (dd, *J* = 17.1, 2.0 Hz, 1 H), 4.76 (dd, *J* = 10.2, 2.0 Hz, 1 H), 4.54 (br s, 1 H), 3.89 (d, *J* = 13.4 Hz, 2 H), 3.51 (dt, *J* = 9.0, 2.3 Hz, 1 H), 3.46 (d, *J* = 13.4 Hz, 2 H), 2.54 (ddd, *J* = 9.0, 6.2, 4.7 Hz, 1 H), 2.35–2.23 (m, 1 H), 2.20–2.08 (m, 1 H), 1.81–1.72 (m, 1 H), 1.65–1.55 (m, 2 H), 1.37–1.22 (m, 2 H), 1.00 (d, *J* = 6.5 Hz, 6 H). ¹³C NMR (75 MHz, CDCl₃): δ 139.0 (2 \times C), 138.7 (CH), 128.9 (4 \times CH), 128.3 (4 \times CH), 127.1 (2 \times CH), 114.3 (CH₂), 70.5 (CH), 60.7 (CH), 53.7 (2 \times CH₂), 35.5 (CH₂), 33.3 (CH₂), 30.2 (CH₂), 26.6 (CH), 23.3 (CH₃), 22.9 (CH₃). MS (70 eV, EI) *m/z* (%): 351 (M⁺, <1), 266 (100). HRMS (70 eV): calcd for C₂₄H₃₃-NO (M⁺), 351.2562; found, 351.2558. IR (neat): 3426, 2955, 2360, 1603, 1495, 1454, 1368 cm⁻¹. *R_f* = 0.42 (hexane/EtOAc 10:1). Anal. Calcd for C₂₄H₃₃-NO: C, 82.00; H, 9.46; N, 3.98; O, 4.55. Found: C, 81.85; H, 9.38; N, 4.03; O, 4.61.

(2S,3S)-3-(Dibenzylamino)-5-methyl-1-phenylhexan-2-ol (4f): colorless oil. [α]²⁵_D = -25.1 (*c* 0.98, CHCl₃). ¹H NMR (200 MHz, CDCl₃): δ 7.33–7.20 (m, 15 H), 4.42 (br s, 1 H), 3.92 (d, *J* = 13.3 Hz, 2 H), 3.75 (dt, *J* = 9.0, 2.3 Hz, 1 H), 3.49 (d, *J* = 13.3 Hz, 2 H), 2.85 (dd, *J* = 13.9, 2.3 Hz, 1 H), 2.69–2.59 (m, 1 H), 2.50 (dd, *J* = 13.9, 9.0 Hz, 1 H), 1.90–1.61 (m, 2 H), 1.41–1.29 (m, 1 H), 0.99 (d, *J* = 6.3 Hz, 3 H), 0.98 (d, *J* = 6.3 Hz, 3 H). ¹³C NMR (75 MHz, CDCl₃): δ 139.2 (C), 139.1 (2 \times C), 129.2 (2 \times CH), 129.0 (4 \times CH), 128.4 (4 \times CH), 128.2 (2 \times CH), 127.1 (2 \times CH), 126.0 (CH), 72.3 (CH), 60.4 (CH), 54.0 (2 \times CH₂), 40.6 (CH₂), 35.9 (CH₂), 26.6 (CH), 23.1 (2 \times CH₃). MS (70 eV, EI) *m/z* (%): 443 (42), 387 (M⁺, 2), 181 (100), 175 (33), 169 (33). HRMS (70 eV): calcd for C₂₇H₃₃-NO (M⁺), 387.2562; found, 387.2581. IR (neat): 3422, 2955, 2357, 1602, 1495, 1454, 1367 cm⁻¹. *R_f* = 0.40 (hexane/EtOAc 20:1). Anal. Calcd for C₂₇H₃₃-NO: C, 83.68; H, 8.58; N, 3.61; O, 4.13. Found: C, 83.81; H, 8.69; N, 3.57; O, 4.19.

(2S,3S)-2-(Dibenzylamino)-1-phenylpentan-3-ol (4g): colorless oil. [α]²⁵_D = +23.4 (*c* 1.49, CHCl₃). ¹H NMR (200 MHz, CDCl₃): δ 7.36–7.27 (m, 15 H), 4.51 (br s, 1 H), 3.96 (d, *J* = 13.3 Hz, 2 H), 3.59 (dt, *J* = 8.3, 2.4 Hz, 1 H), 3.42 (d, *J* = 13.3 Hz, 2 H), 3.14 (dd, *J* = 14.1, 6.3 Hz, 1 H), 2.99–2.89 (m, 1 H), 2.72 (dd, *J* = 14.1, 5.9 Hz, 1 H), 1.58–1.43 (m, 1 H), 1.20–1.09 (m, 1 H), 0.86 (t, *J* = 7.2 Hz, 3 H). ¹³C NMR (50 MHz, CDCl₃): δ 140.5 (C), 138.7 (2 \times C), 129.1 (2 \times CH), 129.0 (4 \times CH), 128.5 (2 \times CH), 128.4 (4 \times CH), 127.2 (2 \times CH), 126.2 (CH), 71.4 (CH), 63.5 (CH), 53.8 (2 \times CH₂), 32.4 (CH₂), 26.9 (CH₂), 9.7 (CH₃). MS (70 eV, EI) *m/z* (%): 359 (M⁺, 1), 300 (100), 268 (15), 181

(16). HRMS (70 eV): calcd for C₂₅H₂₉-NO (M⁺), 359.2249; found, 359.2228. IR (neat): 3421, 3027, 2350, 1602, 1495, 1454, 1374 cm⁻¹. *R_f* = 0.32 (hexane/EtOAc 10:1). Anal. Calcd for C₂₅H₂₉-NO: C, 83.52; H, 8.13; N, 3.90; O, 4.45. Found: C, 83.66; H, 8.21; N, 3.95; O, 4.40.

(2S,3S)-2-(Dibenzylamino)-1-phenylhept-6-en-3-ol (4h): colorless oil. [α]²⁵_D = +25.4 (*c* 1.39, CHCl₃). ¹H NMR (200 MHz, CDCl₃): δ 7.41–7.29 (m, 15 H), 5.78 (dt, *J* = 16.9, 11.0, 6.8 Hz, 1 H), 5.02–4.92 (m, 2 H), 4.51 (br s, 1 H), 3.98 (d, *J* = 13.3 Hz, 2 H), 3.68 (dt, *J* = 8.8, 2.7 Hz, 1 H), 3.48 (d, *J* = 13.3 Hz, 2 H), 3.17 (dd, *J* = 13.9, 6.3 Hz, 1 H), 2.96 (ddd, *J* = 8.8, 6.3, 6.1 Hz, 1 H), 2.74 (dd, *J* = 13.9, 6.1 Hz, 1 H), 2.19–2.07 (m, 2 H), 1.65–1.48 (m, 1 H), 1.35–1.14 (m, 1 H). ¹³C NMR (50 MHz, CDCl₃): δ 140.3 (C), 138.7 (2 \times C), 138.6 (CH), 129.1 (2 \times CH), 128.9 (4 \times CH), 128.5 (2 \times CH), 128.3 (4 \times CH), 127.1 (2 \times CH), 126.1 (CH), 114.3 (CH₂), 69.7 (CH), 63.7 (CH), 53.7 (2 \times CH₂), 33.5 (CH₂), 32.3 (CH₂), 29.7 (CH₂). MS (70 eV, EI) *m/z* (%): 385 (M⁺, 2), 301 (100), 295 (19), 250 (33), 181 (17). HRMS (70 eV): calcd for C₂₇H₃₁-NO (M⁺), 385.2406; found, 385.2395. IR (neat): 3417, 3027, 2924, 2349, 1602, 1495, 1454, 1375 cm⁻¹. *R_f* = 0.35 (hexane/EtOAc 10:1). Anal. Calcd for C₂₇H₃₁-NO: C, 84.11; H, 8.10; N, 3.63; O, 4.15. Found: C, 84.23; H, 8.03; N, 3.59; O, 4.21.

(2S,3S)-3-(Dibenzylamino)-1,4-diphenylbutan-2-ol (4i): colorless oil. [α]²⁵_D = +4.7 (*c* 1.43, CHCl₃). ¹H NMR (200 MHz, CDCl₃): δ 7.42–7.12 (m, 20 H), 3.99 (d, *J* = 13.3 Hz, 2 H), 3.87 (dt, *J* = 8.2, 2.7 Hz, 1 H), 3.43 (d, *J* = 13.3 Hz, 2 H), 3.19 (dd, *J* = 13.1, 5.9 Hz, 1 H), 2.99 (dt, *J* = 8.2, 6.3 Hz, 1 H), 2.86 (dd, *J* = 13.1, 6.5 Hz, 1 H), 2.74 (dd, *J* = 14.1, 2.4 Hz, 1 H), 2.48 (dd, *J* = 14.1, 8.6 Hz, 1 H). ¹³C NMR (50 MHz, CDCl₃): δ 140.3 (C), 139.1 (C), 138.8 (2 \times C), 129.2 (2 \times CH), 129.0 (5 \times CH), 128.6 (2 \times CH), 128.3 (5 \times CH), 128.1 (2 \times CH), 127.1 (2 \times CH), 126.2 (CH), 126.0 (CH), 71.5 (CH), 63.4 (CH), 54.0 (2 \times CH₂), 40.8 (CH₂), 32.3 (CH₂). MS (70 eV, EI) *m/z* (%): 421 (M⁺, <1), 330 (100), 300 (78), 210 (24). HRMS (70 eV): calcd for C₃₀H₃₁-NO (M⁺), 421.2406; found, 421.2412. IR (neat): 3421, 3026, 2343, 1602, 1495, 1454, 1367 cm⁻¹. *R_f* = 0.32 (hexane/EtOAc 10:1). Anal. Calcd for C₃₀H₃₁-NO: C, 85.47; H, 7.41; N, 3.32; O, 3.80. Found: C, 85.58; H, 7.50; N, 3.26; O, 3.75.

(2S,3R)-2-(Dibenzylamino)pentan-3-ol (5a): colorless oil. [α]²⁵_D = +33.0 (*c* 1.26, CHCl₃). ¹H NMR (300 MHz, CDCl₃): δ 7.25–7.12 (m, 10 H), 3.66 (d, *J* = 13.8 Hz, 2 H), 3.45–3.40 (m, 1 H), 3.37 (d, *J* = 13.8 Hz, 2 H), 2.61 (apparent qt, *J* = 6.6 Hz, 1 H), 1.70–1.63 (m, 1 H), 1.25–1.18 (m, 1 H), 1.01 (d, *J* = 6.8 Hz, 3 H), 0.76 (d, *J* = 7.4 Hz, 3 H). ¹³C NMR (50 MHz, CDCl₃): δ 140.1 (2 \times C), 128.7 (4 \times CH), 128.2 (4 \times CH), 126.8 (2 \times CH), 75.2 (CH), 57.0 (CH), 54.7 (2 \times CH₂), 27.1 (CH₂), 10.3 (CH₃), 8.6 (CH₃). HRMS (70 eV): calcd for C₁₈H₂₂-NO (M⁺ – CH₃), 268.1701; found, 268.1689. IR (neat): 3396, 2963, 2359, 102, 1494, 1453, 1377 cm⁻¹. *R_f* = 0.40 (hexane/EtOAc 5:1). Anal. Calcd for C₁₉H₂₅-NO: C, 80.52; H, 8.89; N, 4.94; O, 5.65. Found: C, 80.39; H, 8.80; N, 5.00; O, 5.71.

(2S,3R)-2-(Dibenzylamino)hept-6-en-3-ol (5b): colorless oil. [α]²⁵_D = +40.8 (*c* 1.05, CHCl₃). ¹H NMR (200 MHz, CDCl₃): δ 7.42–7.25 (m, 10 H), 5.87 (ddt, *J* = 17.1, 10.3, 6.7 Hz, 1 H), 5.11–4.97 (m, 2 H), 3.82 (d, *J* = 14.0 Hz, 2 H), 3.65 (apparent t, *J* = 6.7 Hz, 1 H), 3.50 (d, *J* = 14.0 Hz, 2 H), 2.77 (apparent qt, *J* = 6.7 Hz, 1 H), 2.24–1.82 (m, 2 H), 1.52–1.31 (m, 2 H), 1.17 (d, *J* = 6.7 Hz, 3 H). ¹³C NMR (75 MHz, CDCl₃): δ 139.9 (2 \times C), 138.7 (CH), 128.8 (4 \times CH), 128.3 (4 \times CH), 126.8 (2 \times CH), 114.6 (CH₂), 73.0 (CH), 57.1 (CH), 54.6 (2 \times CH₂), 33.3 (CH₂), 30.1 (CH₂), 8.5 (CH₃). MS (70 eV, EI) *m/z* (%): 309 (M⁺, 1), 224 (100). HRMS (70 eV): calcd for C₂₁H₂₇-NO (M⁺), 309.2093; found, 309.2094. IR (neat): 3386, 2923, 2347, 1602, 1494, 1453, 1376 cm⁻¹. *R_f* = 0.20 (hexane/EtOAc 10:1). Anal. Calcd for C₂₁H₂₇-NO: C, 81.51; H, 8.79; N, 4.53; O, 5.17. Found: C, 81.62; H, 8.71; N, 4.57; O, 5.22.

(2R,3S)-3-(Dibenzylamino)-1-phenylbutan-2-ol (5c): colorless oil. [α]²⁵_D = +11.1 (*c* 0.90, CHCl₃). ¹H NMR (200 MHz, CDCl₃): δ 7.51–7.20 (m, 15 H), 3.92 (d, *J* = 13.7 Hz, 2 H), 3.85–3.73 (m,

1 H), 3.60 (d, J = 13.7 Hz, 2 H), 3.42 (dd, J = 13.7, 3.1 Hz, 1 H), 2.87 (apparent qt, J = 6.8 Hz, 1 H), 2.43 (dd, J = 13.7, 9.8 Hz, 1 H), 1.84, (br s, 1 H), 1.28 (d, J = 6.7 Hz, 3 H). ^{13}C NMR (50 MHz, CDCl_3): δ 140.0 (2 \times C), 139.3 (C), 129.2 (2 \times CH), 128.7 (4 \times CH), 128.4 (2 \times CH), 128.2 (4 \times CH), 126.8 (2 \times CH), 126.2 (CH), 74.6 (CH), 51.2 (CH), 54.5 (2 \times CH_2), 41.4 (CH₂), 8.5 (CH₃). MS (70 eV, EI) m/z (%): 345 (M⁺, 1), 224 (100). HRMS (70 eV): calcd for $\text{C}_{24}\text{H}_{27}\text{NO}$ (M⁺), 345.2093; found, 345.2102. IR (neat): 3419, 3027, 2352, 1602, 1494, 1453, 1377 cm⁻¹. R_f = 0.26 (hexane/EtOAc 10:1). Anal. Calcd for $\text{C}_{24}\text{H}_{27}\text{NO}$: C, 83.44; H, 7.88; N, 4.05; O, 4.63. Found: C, 83.58; H, 7.79; N, 4.10; O, 4.58.

(3R,4S)-4-(Dibenzylamino)-6-methylheptan-3-ol (5d): colorless oil. $[\alpha]^{25}_{\text{D}} = +1.5$ (c 1.13, CHCl_3). ^1H NMR (200 MHz, CDCl_3): δ 7.37–7.26 (m, 10 H), 3.70 (AB syst., J = 14.5 Hz, 4 H), 3.66–3.61 (m, 1 H), 2.80–2.72 (m, 1 H), 1.87–1.04 (m, 5 H), 0.97 (t, J = 7.8 Hz, 3 H), 0.95 (d, J = 6.7 Hz, 3 H), 0.76 (d, J = 6.7 Hz, 3 H). ^{13}C NMR (50 MHz, CDCl_3): δ 140.2 (2 \times C), 128.9 (4 \times CH), 128.2 (4 \times CH), 126.9 (2 \times CH), 72.2 (CH), 58.1 (CH), 55.0 (2 \times CH_2), 34.4 (CH₂), 27.5 (CH₂), 24.7 (CH), 23.1 (CH₃), 22.7 (CH₃), 11.1 (CH₃). MS (70 eV, EI) m/z (%): 310 (M⁺ – CH_3 , <1), 266 (46), 91 (100). HRMS (70 eV): calcd for $\text{C}_{21}\text{H}_{28}\text{NO}$ (M⁺ – CH_3), 310.2171; found, 31.2169. IR (neat): 3448, 2956, 2350, 1494, 1455, 1364 cm⁻¹. R_f = 0.26 (hexane/EtOAc 10:1). Anal. Calcd for $\text{C}_{22}\text{H}_{29}\text{NO}$: C, 81.18; H, 9.60; N, 4.30; O, 4.92. Found: C, 81.36; H, 9.51; N, 4.34; O, 4.87.

(5R,6S)-6-(Dibenzylamino)-8-methylnon-1-en-5-ol (5e): white solid. $[\alpha]^{25}_{\text{D}} = +0.2$ (c 2.31, CHCl_3). ^1H NMR (300 MHz, CDCl_3): δ 7.25–7.15 (m, 10 H), 5.74 (ddt, J = 17.2, 10.2, 6.6 Hz, 1 H), 5.00–4.93 (m, 1 H), 4.92–4.87 (m, 1 H), 3.70–3.63 (m, 1 H), 3.58 (s, 4 H), 2.66 (dt, J = 7.0, 4.0 Hz, 1 H), 2.25–2.08 (m, 2 H), 2.05–1.92 (m, 1 H), 1.75–1.62 (m, 1 H), 1.57–1.33 (m, 3 H), 1.25–1.13 (m, 1 H), 0.84 (d, J = 6.7 Hz, 3 H), 0.68 (d, J = 6.5, 3 H). ^{13}C NMR (75 MHz, CDCl_3): δ 140.0 (2 \times C), 138.4 (CH), 128.9 (4 \times CH), 128.2 (4 \times CH), 127.0 (2 \times CH), 114.8 (CH₂), 70.0 (CH), 58.5 (CH), 55.1 (2 \times CH_2), 34.4 (CH₂), 33.6 (CH₂), 30.8 (CH₂), 24.7 (CH), 22.9 (CH₃), 22.8 (CH₃). MS (70 eV, EI) m/z (%): 351 (M⁺, <1), 266 (55), 91 (36), 69 (100). HRMS (70 eV): calcd for $\text{C}_{24}\text{H}_{33}\text{NO}$ (M⁺), 351.2562; found, 351.2553. IR (neat): 3387, 2952, 2361, 1603, 1494, 1453, 1367 cm⁻¹. R_f = 0.29 (hexane/EtOAc 10:1). Anal. Calcd for $\text{C}_{24}\text{H}_{33}\text{NO}$: C, 82.00; H, 9.46; N, 3.98; O, 4.55. Found: C, 81.86; H, 9.58; N, 3.93; O, 4.61.

(2R,3S)-3-(Dibenzylamino)-5-methyl-1-phenylhexan-2-ol (5f): white solid. $[\alpha]^{25}_{\text{D}} = -38.0$ (c 1.25, CHCl_3). ^1H NMR (300 MHz, CDCl_3): δ 7.41–7.20 (m, 15 H), 4.19–4.14 (m, 1 H), 3.82 (d, J = 13.7 Hz, 2 H), 3.57 (d, J = 13.7 Hz, 2 H), 2.87 (dd, J = 13.5, 5.0 Hz, 1 H), 2.77–2.72 (m, 1 H), 2.66 (dd, J = 13.5, 8.9 Hz, 1 H), 1.99–1.87 (m, 1 H), 1.73 (ddd, J = 13.9, 8.5, 5.2 Hz, 1 H), 1.34–1.29 (m, 1 H), 0.98 (d, J = 6.6 Hz, 3 H), 0.67 (d, J = 6.6 Hz, 3 H). ^{13}C NMR (75 MHz, CDCl_3): δ 140.2 (2 \times C), 138.9 (C), 129.3 (2 \times CH), 129.0 (4 \times CH), 128.6 (2 \times CH), 128.1 (4 \times CH), 126.7 (2 \times CH), 126.3 (CH), 71.7 (CH), 57.7 (CH), 54.6 (2 \times CH_2), 42.1 (CH₂), 34.6 (CH₂), 24.6 (CH), 23.5 (CH₃), 22.2 (CH₃). MS (70 eV, EI) m/z (%): 387 (M⁺, 1), 278 (26), 266 (100). HRMS (70 eV): calcd for $\text{C}_{27}\text{H}_{33}\text{NO}$ (M⁺), 387.2562; found, 387.2571. IR (neat): 3389, 2948, 2357, 1601, 1493, 1454, 1362 cm⁻¹. R_f = 0.22 (hexane/EtOAc 10:1). Anal. Calcd for $\text{C}_{27}\text{H}_{33}\text{NO}$: C, 83.68; H, 8.58; N, 3.61; O, 4.13. Found: C, 83.56; H, 8.65; N, 3.65; O, 4.09.

(2S,3R)-2-(Dibenzylamino)-1-phenylpentan-3-ol (5g): colorless oil. $[\alpha]^{25}_{\text{D}} = -9.6$ (c 1.11, CHCl_3). ^1H NMR (300 MHz, CDCl_3): δ 7.28–7.05 (m, 15 H), 3.88–3.82 (m, 1 H), 3.67 (d, J = 13.8 Hz, 2 H), 3.56 (d, J = 13.8 Hz, 2 H), 3.43–3.32 (m, 1 H), 3.02–2.89 (m, 2 H), 2.70 (dd, J = 12.6, 5.6 Hz, 1 H), 1.62–1.54 (m, 1 H), 1.35–1.23 (m, 1 H), 0.79 (t, J = 7.4 Hz, 3 H). ^{13}C NMR (75 MHz, CDCl_3): δ 140.6 (C), 139.7 (2 \times C), 129.3 (2 \times CH), 128.7 (4 \times CH), 128.3 (2 \times CH), 128.2 (4 \times CH), 126.9 (2 \times CH), 125.9 (CH), 73.3 (CH), 63.0 (CH), 55.0 (2 \times CH_2), 31.8 (CH₂), 27.6

(CH₂), 10.8 (CH₃). MS (70 eV, EI) m/z (%): 359 (M⁺, <1), 300 (28), 91 (24), 69 (100). HRMS (70 eV): calcd for $\text{C}_{25}\text{H}_{29}\text{NO}$ (M⁺), 359.2249; found, 359.2244. IR (neat): 3427, 2929, 2360, 1602, 1494, 1454, 1365 cm⁻¹. R_f = 0.13 (hexane/EtOAc 10:1). Anal. Calcd for $\text{C}_{25}\text{H}_{29}\text{NO}$: C, 83.52; H, 8.13; N, 3.90; O, 4.45. Found: C, 83.67; H, 8.21; N, 3.95; O, 4.51.

(2S,3R)-2-(Dibenzylamino)-1-phenylhept-6-en-3-ol (5h): colorless oil. $[\alpha]^{25}_{\text{D}} = +17.4$ (c 1.34, CHCl_3). ^1H NMR (300 MHz, CDCl_3): δ 7.26–7.10 (m, 15 H), 5.73 (ddt, J = 17.1, 10.2, 6.7 Hz, 1 H), 4.98–4.88 (m, 2 H), 3.75–3.63 (m, 4 H), 3.57 (d, J = 13.7 Hz, 2 H), 3.07–2.94 (m, 2 H), 2.74 (dd, J = 12.4, 5.7 Hz, 1 H), 2.19–2.09 (m, 1 H), 2.01–1.89 (m, 1 H), 1.74–1.64 (m, 1 H), 1.44–1.35 (m, 1 H). ^{13}C NMR (75 MHz, CDCl_3): δ 140.4 (C), 139.6 (2 \times C), 138.3 (CH), 129.2 (2 \times CH), 128.7 (4 \times CH), 128.2 (2 \times CH), 128.1 (4 \times CH), 126.9 (2 \times CH), 125.9 (CH), 114.8 (CH₂), 71.0 (CH), 63.2 (CH), 55.0 (2 \times CH_2), 33.7 (CH₂), 31.9 (CH₂), 30.5 (CH₂). MS (70 eV, EI) m/z (%): 385 (M⁺, <1), 300 (100), 301 (27). HRMS (70 eV): calcd for $\text{C}_{27}\text{H}_{31}\text{NO}$ (M⁺), 385.2406; found, 385.2381. IR (neat): 3432, 3026, 2360, 1602, 1494, 1453, 1364 cm⁻¹. R_f = 0.16 (hexane/EtOAc 10:1). Anal. Calcd for $\text{C}_{27}\text{H}_{31}\text{NO}$: C, 84.11; H, 8.10; N, 3.63; O, 4.15. Found: C, 84.28; H, 8.01; N, 3.58; O, 4.21.

(2S,3R)-3-(Dibenzylamino)-1,4-diphenylbutan-2-ol (5i): white solid. $[\alpha]^{25}_{\text{D}} = -5.7$ (c 1.71, CHCl_3). ^1H NMR (300 MHz, CDCl_3): δ 7.29–7.02 (m, 20 H), 4.01–3.97 (m, 1 H), 3.65 (AB syst., J = 15.0 Hz, 4 H), 3.09–3.00 (m, 2 H), 2.96 (dd, J = 13.6, 3.8 Hz, 1 H), 2.89 (dd, J = 10.9, 3.1 Hz, 1 H), 2.44 (dd, J = 13.6, 9.8 Hz, 1 H). ^{13}C NMR (75 MHz, CDCl_3): δ 140.7 (C), 139.7 (C), 138.9 (2 \times C), 129.4 (2 \times CH), 129.2 (2 \times CH), 128.7 (4 \times CH), 128.5 (2 \times CH), 128.2 (2 \times CH), 128.1 (4 \times CH), 126.8 (2 \times CH), 126.3 (CH), 125.8 (CH), 72.9 (CH), 62.8 (CH), 54.8 (2 \times CH₂), 41.9 (CH₂), 32.0 (CH₂). HRMS (70 eV): calcd for $\text{C}_{30}\text{H}_{31}\text{NO}$ (M⁺) 421.2406; found, 421.2413. IR (neat): 3420, 3028, 2359, 1602, 1494, 1454, 1364 cm⁻¹. R_f = 0.17 (hexane/EtOAc 10:1). Anal. Calcd for $\text{C}_{30}\text{H}_{31}\text{NO}$: C, 85.47; H, 7.41; N, 3.32; O, 3.80. Found: C, 85.33; H, 7.50; N, 3.26; O, 3.86.

General Procedure of Synthesis of Compounds 6, 7, 8, and 9. To a stirred solution of the corresponding aminoepoxide **1** or **2** (0.2 mmol) in THF (1 mL), LiAlH₄ or LiAlD₄ (0.3 mmol, 0.3 mL, 1 M in THF) was added at 0 °C. After stirring at this temperature for 2 h, an aqueous saturated solution of NH₄Cl (5 mL) was added, and the mixture was stirred at room temperature for 5 min. Then, the aqueous phase was extracted with diethyl ether (3 \times 5 mL), and the combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. Flash column chromatography on silica gel (hexane/EtOAc 10:1) provided pure compounds **6**, **7**, **8**, or **9**.

(2S,3S)-3-(Dibenzylamino)butan-2-ol (6a): colorless oil. $[\alpha]^{25}_{\text{D}} = +75.0$ (c 2.30, CHCl_3). ^1H NMR (300 MHz, CDCl_3): δ 7.38–7.26 (m, 10 H), 4.41 (br s, 1 H), 3.87 (d, J = 13.3 Hz, 2 H), 3.67 (dq, J = 9.3, 6.1 Hz, 1 H), 3.36 (d, J = 13.3 Hz, 2 H), 2.53 (dq, J = 9.3, 6.6 Hz, 1 H), 1.12 (d, J = 6.1 Hz, 3 H), 1.05 (d, J = 6.6 Hz, 3 H). ^{13}C NMR (75 MHz, CDCl_3): δ 138.8 (2 \times C), 128.9 (4 \times CH), 128.5 (4 \times CH), 127.1 (2 \times CH), 66.9 (CH), 60.2 (CH), 53.3 (2 \times CH_2), 19.3 (CH₃), 7.8 (CH₃). MS (70 eV, EI) m/z (%): 251 (M⁺ – H₂O, <1), 224 (92), 91 (100). HRMS (70 eV): calcd for $\text{C}_{18}\text{H}_{21}\text{N}$ (M⁺ – H₂O), 251.1674; found, 251.1702. IR (neat): 3426, 2971, 2351, 1603, 1495, 1453, 1383 cm⁻¹. R_f = 0.17 (hexane/EtOAc 10:1). Anal. Calcd for $\text{C}_{18}\text{H}_{21}\text{NO}$: C, 80.26; H, 8.61; N, 5.20; O, 5.94. Found: C, 80.40; H, 8.52; N, 5.15; O, 5.99.

(2S,3S)-3-(Dibenzylamino)-5-methylhexan-2-ol (6b): colorless oil. $[\alpha]^{25}_{\text{D}} = +60.9$ (c 2.18, CHCl_3). ^1H NMR (300 MHz, CDCl_3): δ 7.38–7.26 (m, 10 H), 4.48 (br s, 1 H), 3.90 (d, J = 13.4 Hz, 2 H), 3.67 (dq, J = 9.0, 6.1 Hz, 1 H), 3.47 (d, J = 13.4 Hz, 2 H), 2.48 (ddd, J = 9.0, 6.6, 4.4 Hz, 1 H), 1.84–1.77 (m, 1 H), 1.63 (ddd, J = 14.2, 8.2, 4.4 Hz, 1 H), 1.16 (d, J = 6.1 Hz, 3 H), 1.08–1.04 (m, 1 H), 1.02 (d, J = 6.6 Hz, 6 H). ^{13}C NMR (50 MHz, CDCl_3): δ 139.1 (2 \times C), 128.8 (4 \times CH), 128.3 (4 \times CH), 127.0 (2 \times CH), 67.2 (CH), 62.6 (CH), 53.7 (2 \times CH_2), 35.3 (CH₂),

26.4 (CH), 23.3 (CH₃), 22.8 (CH₃), 19.7 (CH₃). MS (70 eV, EI) *m/z* (%): 311 (M⁺, <1), 266 (100), 181 (11). HRMS (70 eV): calcd for C₂₁H₂₉NO (M⁺), 311.2249; found, 311.2266. IR (neat): 3441, 2956, 2360, 1603, 1495, 1454, 1377 cm⁻¹. *R_f* = 0.24 (hexane/EtOAc 10:1). Anal. Calcd for C₂₁H₂₉NO: C, 80.98; H, 9.38; N, 4.50; O, 5.14. Found: C, 81.15; H, 9.30; N, 4.56; O, 5.08.

(2S,3S)-3-(Dibenzylamino)-4-phenylbutan-2-ol (6c): white solid. [α]²⁵_D = +49.2 (c 1.60, CHCl₃). ¹H NMR (300 MHz, CDCl₃): δ 7.39–7.26 (m, 15 H), 4.41 (br s, 1 H), 3.96 (d, *J* = 13.3 Hz, 2 H), 3.81 (dq, *J* = 8.7, 6.0 Hz, 1 H), 3.44 (d, *J* = 13.3 Hz, 2 H), 3.14 (dd, *J* = 14.2, 6.4 Hz, 1 H), 2.87 (ddd, *J* = 8.7, 6.4, 6.3 Hz, 1 H), 2.72 (dd, *J* = 14.2, 6.3 Hz, 1 H), 1.06 (d, *J* = 6.0 Hz, 3 H). ¹³C NMR (75 MHz, CDCl₃): δ 140.4 (C), 138.8 (2 × C), 129.1 (2 × CH), 128.9 (4 × CH), 128.4 (2 × CH), 128.3 (4 × CH), 127.1 (2 × CH), 126.1 (CH), 66.5 (CH), 65.9 (CH), 53.7 (2 × CH₂), 32.1 (CH₂), 20.2 (CH₃). MS (70 eV, EI) *m/z* (%): 345 (M⁺, <1), 300 (100). HRMS (70 eV): calcd for C₂₄H₂₇NO (M⁺), 345.2093; found, 345.2086. IR (neat): 3361, 3025, 2370, 1602, 1495, 1454, 1378 cm⁻¹. *R_f* = 0.20 (hexane/EtOAc 10:1). Anal. Calcd for C₂₄H₂₇NO: C, 83.44; H, 7.88; N, 4.05; O, 4.63. Found: C, 83.30; H, 7.79; N, 4.10; O, 4.69.

(2R,3S)-3-(Dibenzylamino)butan-2-ol (7a): white solid. [α]²⁵_D = +78.8 (c 1.46, CHCl₃). ¹H NMR (300 MHz, CDCl₃): δ 7.42–7.27 (m, 10 H), 3.82 (d, *J* = 13.7 Hz, 2 H), 3.50 (d, *J* = 13.7 Hz, 2 H), 3.43–3.35 (m, 1 H), 2.68 (apparent qt, *J* = 6.7 Hz, 1 H), 2.14 (br s, 1 H), 1.26 (d, *J* = 6.4 Hz, 3 H), 1.16 (d, *J* = 6.7 Hz, 3 H). ¹³C NMR (75 MHz, CDCl₃): δ 140.0 (2 × C), 128.6 (4 × CH), 128.1 (4 × CH), 126.8 (2 × CH), 70.0 (CH), 58.4 (CH), 54.6 (2 × CH₂), 21.0 (CH₃), 8.5 (CH₃). MS (70 eV, EI) *m/z* (%): 254 (M⁺ – CH₃, <1), 224 (100), 181 (20), 119 (28). HRMS (70 eV): calcd for C₁₇H₂₀NO (M⁺ – CH₃), 254.1545; found, 254.1545. IR (neat): 3262, 3022, 2970, 2356, 1602, 1494, 1453, 1364 cm⁻¹. *R_f* = 0.44 (hexane/EtOAc 3:1). Anal. Calcd for C₁₈H₂₃NO: C, 80.26; H, 8.61; N, 5.20; O, 5.94. Found: C, 80.42; H, 8.70; N, 5.24; O, 5.89.

(2R,3S)-3-(Dibenzylamino)-5-methylhexan-2-ol (7b): colorless oil. [α]²⁵_D = +34.2 (c 1.34, CHCl₃). ¹H NMR (300 MHz, CDCl₃): δ 7.29–7.13 (m, 10 H), 3.87 (dq, *J* = 6.6, 4.2 Hz, 1 H), 3.60 (AB syst., *J* = 13.6 Hz, 4 H), 3.63 (ddd, *J* = 6.9, 6.8, 4.2 Hz, 1 H), 2.33 (br s, 1 H), 1.76–1.63 (m, 1 H), 1.55–1.46 (m, 1 H), 1.25–1.16 (m, 1 H), 1.11 (d, *J* = 6.6 Hz, 3 H), 0.85 (d, *J* = 6.5 Hz, 3 H), 0.71 (d, *J* = 6.5 Hz, 3 H). ¹³C NMR (75 MHz, CDCl₃): δ 140.0 (2 × C), 128.9 (4 × CH), 128.2 (4 × CH), 126.9 (2 × CH), 66.5 (CH), 59.1 (CH), 55.1 (2 × CH₂), 34.5 (CH₂), 24.8 (CH), 22.9 (CH₃), 22.8 (CH₃), 20.7 (CH₃). MS (70 eV, EI) *m/z* (%): 311 (M⁺, <1), 266 (100), 91 (31). HRMS (70 eV): calcd for C₂₁H₂₉NO (M⁺), 311.2249; found, 311.2247. IR (neat): 3419, 2955, 2350, 1603, 1494, 1454, 1367 cm⁻¹. *R_f* = 0.21 (hexane/EtOAc 10:1). Anal. Calcd for C₂₁H₂₉NO: C, 80.98; H, 9.38; N, 4.50; O, 5.14. Found: C, 80.80; H, 9.46; N, 4.44; O, 5.19.

(2R,3S)-3-(Dibenzylamino)-4-phenylbutan-2-ol (7c): colorless oil. [α]²⁵_D = +13.7 (c 1.52, CHCl₃). ¹H NMR (300 MHz, CDCl₃): δ 7.25–7.10 (m, 15 H), 3.84–3.80 (m, 1 H), 3.74 (d, *J* = 13.8 Hz, 2 H), 3.55 (d, *J* = 13.8 Hz, 2 H), 3.02 (dd, *J* = 13.3, 6.7 Hz, 1 H), 2.85 (dt, *J* = 6.7, 4.8 Hz, 1 H), 2.74 (dd, *J* = 13.3, 6.6 Hz, 1 H), 2.18 (br s, 1 H), 1.17 (d, *J* = 6.5 Hz, 3 H). ¹³C NMR (75 MHz, CDCl₃): δ 140.4 (C), 139.5 (2 × C), 129.2 (2 × CH), 128.7 (4 × CH), 128.3 (2 × CH), 128.2 (4 × CH), 126.9 (2 × CH), 125.9 (CH), 67.6 (CH), 64.0 (CH), 55.1 (2 × CH₂), 32.0 (CH₂), 20.9 (CH₃). MS (70 eV, EI) *m/z* (%): 345 (M⁺, <1), 300 (97), 91 (100). HRMS (70 eV): calcd for C₂₄H₂₇NO (M⁺), 345.2093; found, 345.2103. IR (neat): 3418, 3027, 2360, 1602, 1494, 1454, 1372 cm⁻¹. *R_f* = 0.37 (hexane/EtOAc 5:1). Anal. Calcd for C₂₄H₂₇NO: C, 83.44; H, 7.88; N, 4.05; O, 4.63. Found: C, 83.58; H, 7.97; N, 4.00; O, 4.69.

(2S,3S)-1-Deuterium-3-(dibenzylamino)butan-2-ol (8a): colorless oil. [α]²⁵_D = +107.3 (c 1.45, CHCl₃). ¹H NMR (300 MHz, CDCl₃): δ 7.26–7.14 (m, 10 H), 4.27 (br s, 1 H), 3.75 (d, *J* = 13.3 Hz, 2 H), 3.54 (dt, *J* = 9.4, 5.9 Hz, 1 H), 3.23 (d, *J* = 13.3

Hz, 2 H), 2.40 (dq, *J* = 9.4, 6.6 Hz, 1 H), 0.98 (d, *J* = 5.9 Hz, 2 H), 0.93 (d, *J* = 6.6 Hz, 3 H). ¹³C NMR (75 MHz, CDCl₃): δ 138.9 (2 × C), 128.9 (4 × CH), 128.3 (4 × CH), 127.1 (2 × CH), 66.8 (CH), 60.1 (CH), 53.2 (2 × CH₂), 19.0 (t, *J* = 76.4 Hz, CH₂D), 7.7 (CH₃). MS (70 eV, EI) *m/z* (%): 270 (M⁺, <1), 224 (84), 91 (100), 69 (27), 58 (43). HRMS (70 eV): calcd for C₁₈H₂₂DNO (M⁺), 270.1842; found, 270.1858. IR (neat): 3431, 2969, 2361, 1603, 1495, 1453, 1377 cm⁻¹. *R_f* = 0.21 (hexane/EtOAc 10:1). Anal. Calcd for C₁₈H₂₂DNO: C, 79.96; H, 8.95; N, 5.18; O, 5.92. Found: C, 79.79; H, 9.03; N, 5.13; O, 5.98.

(2S,3S)-1-Deuterium-3-(dibenzylamino)-4-phenylbutan-2-ol (8c): white solid. [α]²⁵_D = +35.8 (c 1.97, CHCl₃). ¹H NMR (300 MHz, CDCl₃): δ 7.28–7.11 (m, 15 H), 4.27 (br s, 1 H), 3.82 (d, *J* = 13.3 Hz, 2 H), 3.67 (dt, *J* = 8.9, 6.0 Hz, 1 H), 3.30 (d, *J* = 13.3 Hz, 2 H), 3.01 (dd, *J* = 14.3, 6.3 Hz, 1 H), 2.73 (dt, *J* = 8.9, 6.3 Hz, 1 H), 2.58 (dd, *J* = 14.3, 6.3 Hz, 1 H), 0.90 (d, *J* = 6.0 Hz, 2 H). ¹³C NMR (75 MHz, CDCl₃): δ 140.4 (C), 138.8 (2 × C), 129.1 (2 × CH), 129.0 (4 × CH), 128.5 (2 × CH), 128.4 (4 × CH), 127.2 (2 × CH), 126.1 (CH), 66.5 (CH), 66.0 (CH), 53.8 (2 × CH₂), 32.1 (CH₂), 20.0 (t, *J* = 76.4 Hz, CH₂D). MS (70 eV, EI) *m/z* (%): 346 (M⁺, <1), 300 (80), 210 (90), 91 (100). HRMS (70 eV): calcd for C₂₄H₂₆DNO (M⁺), 346.2155; found, 346.2158. IR (neat): 3407, 3054, 2360, 1603, 1496, 1454, 1374 cm⁻¹. *R_f* = 0.22 (hexane/EtOAc 10:1). Anal. Calcd for C₂₄H₂₆DNO: C, 83.19; H, 8.14; N, 4.04; O, 4.62. Found: C, 83.06; H, 8.23; N, 4.08; O, 4.67.

(2R,3S)-1-Deuterium-3-(dibenzylamino)butan-2-ol (9a): white solid. [α]²⁵_D = +86.5 (c 0.99, CHCl₃). ¹H NMR (300 MHz, CDCl₃): δ 7.29–7.14 (m, 10 H), 3.69 (d, *J* = 14.0 Hz, 2 H), 3.36 (d, *J* = 14.0 Hz, 2 H), 3.29–3.22 (m, 1 H), 2.55 (apparent qt, *J* = 6.7 Hz, 1 H), 1.84 (br s, 1 H), 1.12 (d, *J* = 6.2 Hz, 2 H), 1.03 (d, *J* = 6.8 Hz, 3 H). ¹³C NMR (75 MHz, CDCl₃): δ 140.0 (2 × C), 128.7 (4 × CH), 128.2 (4 × CH), 126.8 (2 × CH), 69.6 (CH), 58.4 (CH), 54.6 (2 × CH₂), 20.7 (t, *J* = 76.4 Hz, CH₂D), 8.5 (CH₃). MS (70 eV, EI) *m/z* (%): 255 (M⁺ – CH₃, <1), 224 (88), 91 (100). HRMS (70 eV): calcd for C₁₇H₁₉DNO (M⁺ – CH₃), 255.1608; found, 255.1615. IR (neat): 3316, 2933, 2360, 1602, 1494, 1452, 1326 cm⁻¹. *R_f* = 0.31 (hexane/EtOAc 5:1). Anal. Calcd for C₁₈H₂₂DNO: C, 79.96; H, 8.95; N, 5.18; O, 5.92. Found: C, 79.81; H, 89.03; N, 5.14; O, 5.97.

(2R,3S)-1-Deuterium-3-(dibenzylamino)-4-phenylbutan-2-ol (9c): colorless oil. [α]²⁵_D = +22.5 (c 1.99, CHCl₃). ¹H NMR (300 MHz, CDCl₃): δ 7.28–7.13 (m, 15 H), 3.83 (apparent q, *J* = 5.9 Hz, 1 H), 3.75 (d, *J* = 13.8 Hz, 2 H), 3.58 (d, *J* = 13.8 Hz, 2 H), 3.04 (dd, *J* = 13.3, 6.8 Hz, 1 H), 2.94 (dt, *J* = 6.7, 4.9 Hz, 1 H), 2.75 (dd, *J* = 13.3, 6.6 Hz, 1 H), 2.10 (br s, 1 H), 1.18 (d, *J* = 6.5 Hz, 2 H). ¹³C NMR (75 MHz, CDCl₃): δ 140.5 (C), 139.6 (2 × C), 129.2 (2 × CH), 128.7 (4 × CH), 128.3 (2 × CH), 128.2 (4 × CH), 126.9 (2 × CH), 125.9 (CH), 67.5 (CH), 64.0 (CH), 55.1 (2 × CH₂), 32.0 (CH₂), 20.6 (t, *J* = 76.4 Hz, CH₂D). MS (70 eV, EI) *m/z* (%): 346 (M⁺, <1), 300 (32), 208 (27), 91 (100), 69 (41). HRMS (70 eV): calcd for C₂₄H₂₆DNO (M⁺), 346.2155; found, 346.2147. IR (neat): 3412, 3027, 2360, 1602, 1494, 1453, 1364 cm⁻¹. *R_f* = 0.36 (hexane/EtOAc 5:1). Anal. Calcd for C₂₄H₂₆DNO: C, 83.19; H, 8.14; N, 4.04; O, 4.62. Found: C, 83.25; H, 8.07; N, 4.09; O, 4.56.

Acknowledgment. We thank Ministerio de Ciencia y Tecnología (Grant CTQ2004-1191/BQU) for financial support and Euan Goddard for his revision of the English. J.M.C. thanks Carmen Fernández-Flórez for her time. V del S. thanks Principado de Asturias for a contract investigation.

Supporting Information Available: ¹³C NMR spectra of **4**, **5**, **6**, **7**, **8**, and **9**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

JO0606756